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ABSTRACT
More than 130 mutations in human mitochondrial tRNA (mt-tRNA) genes have been correlated with a variety of
neurodegenerative and neuromuscular disorders. Their molecular impacts are of mosaic type, affecting various stages of tRNA
biogenesis, structure, and/or functions in mt-translation. Knowledge of mammalian mt-tRNA structures per se remains scarce
however. Primary and secondary structures deviate from classical tRNAs, while rules for three-dimensional (3D) folding are
almost unknown. Here, we take advantage of a myopathy-related mutation A7526G (A9G) in mt-tRNAAsp to investigate both
the primary molecular impact underlying the pathology and the role of nucleotide 9 in the network of 3D tertiary interactions.
Experimental evidence is presented for existence of a 9-12-23 triple in human mt-tRNAAsp with a strongly conserved interaction
scheme in mammalian mt-tRNAs. Mutation A7526G disrupts the triple interaction and in turn reduces aspartylation efficiency.
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INTRODUCTION
The human mitochondrial (mt) genome codes for 13 pro-
teins, 2 rRNAs, and 22 tRNAs. The 13 proteins are subunits
of the respiratory chain complexes and contribute to ATP
synthesis. The 22 tRNA genes are hotspots for mutations,
which are either polymorphisms (neutral consequences) or
related to diseases (see the MITOMAP database) (Ingman
and Gyllensten 2006). Understanding the molecular impact
of mutations on the multiple facets of tRNA biogenesis,
structure, and function has been tackled by several com-
plementary in vitro and in vivo studies. The mosaic of
results collected so far favors diverse molecular impacts,
with, in some cases, cumulative effects (Wallace et al. 1999;
Florentz et al. 2003; Jacobs 2003; DiMauro 2006; Shapira
2006). Due to the lack of knowledge on structure/function
relationships of mammalian mt-tRNAs, already recognized
as ‘‘bizarre’’ at the primary and secondary structural levels
(e.g., Helm et al. 2000), pathologic or polymorphic inci-
dence of a mutation can still not be predicted (Florentz and
Sissler 2001; Florentz et al. 2003; Levinger et al. 2004;
McFarland et al. 2004). Knowledge on three-dimensional
(3D) folding rules is scarce.
Human mt-tRNAAsp is a typical representative of the
structural degeneration of mammalian mt-tRNAs. Like 14
out of the 22 mt-tRNAs, it has a biased A-, U-, and C-rich
nucleotide content. It can fold into a theoretical secondary
cloverleaf structure but with small D- and T-loops, and
several conserved nucleotides that would be expected to
induce and stabilize the 3D fold (Helm et al. 2000) char-
acteristic of classical tRNAs (Juehling et al. 2009) appear to
be absent. The gene for this tRNA is affected by mutation
A7526G in a patient with a mitochondrial myopathy
(Seneca et al. 2005). The molecular impact of this mutation
is unknown but raises an interesting structural question.
Indeed, mutation A7526G generates a nucleotide transi-
tion at a position of potential structural importance for the
folding and the 3D structure of the RNA, namely position 9
(classical tRNA numbering, Juehling et al. 2009). Investi-
gation of this mutation should assist not only in gaining a
better understanding of the initial molecular impact respon-
sible for pathology but also in gaining a better knowledge of
rules governing human mt-tRNA 3D structures.
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Here, we present a mutagenic analysis involving func-
tional and structural studies in solution on human mt-
tRNAAsp derivatives. Enzymatic structural probing on both
wild-type and mutant in vitro transcripts reveals a primary
impact of mutation A7526G on structure, which subse-
quently hampers aminoacylation properties of mt-tRNAAsp.
Compensatory mutations restore both activity and struc-
ture and strongly support the existence of a tertiary inter-
action between nucleotide 9 and base-pair 12-23 within the
D-stem. Compilation of sequences within the specifically
dedicated database ‘‘Mamit-tRNA’’ (Pu¨tz et al. 2007) ex-
tends the existence of this tertiary interaction to 97.8%
of all known mammalian mt-tRNAAsp sequences and to a
large group of additional mammalian mt-tRNAs.
RESULTS AND DISCUSSION
Predicted impact of mutation A7526G (A9G)
on mt-tRNAAsp structure
In classical tRNAs (i.e., from bacteria, archae, and cytosol
of eukaryotes), nine tertiary interactions sustain the 3D
fold (Fig. 1), three in and between D- and T-loops, and six
forming the core of the structure (Kim et al. 1974; Westhof
et al. 1985; for review, see Giege´ et al. 1993; Dirheimer et al.
1995). Myopathy-related mutation A7526G (Seneca et al.
2005) affects nucleotide at position 9 in tRNAAsp, poten-
tially part of the 3D network. Mutation A9G (mutant G9/
A12-U23) would break the link between residues 9 and 23
present in the wild-type triple A9/A12-U23. To investigate
this hypothesis, the structure as well as the function of
wild-type and mutant G9/A12-U23 mt-tRNAAsp were com-
pared. Solution structures were investigated by enzymatic
probing while the aminoacylation properties were estab-
lished in the presence of recombinant human mt aspartyl-
tRNA synthetase (mt-AspRS). Two additional variants,
tRNAAspG9/G12-C23 (with a double transition in the
D-stem) and variant tRNAAspG9/U12-A23 (with a dou-
ble transversion) were also studied.
Comparative structural investigation
Structural probing of the transcripts was performed with
nuclease S1 (cleaves single-stranded regions) and ribonu-
clease V1 (cleaves double-stranded or highly structured re-
gions) (Giege´ et al. 1999) on 59-end labeled tRNAs. Typical
cleavage profiles are shown in Figure 2. They fit with
cloverleaf structures of the RNAs, stems being cleaved by
ribonuclease V1 and loops by nuclease S1. Interestingly,
only subtle but significant differences in cleavage intensities
appear. There is no general structural breakdown for the
pathology-related mutant. Differences in profiles are high-
lighted in Figure 3, A–D. None of the phosphodiester bonds
located 39 of residues 9, 12, and 23, are cleaved by nuclease
S1, but all are cleaved by ribonuclease V1. This is in agree-
ment with involvement of the three nucleotides in a higher-
order structure, in wild type as well as in each of the three
other molecules. Focus on base-pair 12-23 in the D-stem
reveals stronger sensitivity to V1 ribonuclease in mutant
mt-tRNAAspG9/A12-U23 and in variant mt-tRNAAspG9/
G12-C23, as compared with the cleavage pattern in wild-
type tRNAAsp and variant G9/U12-A23. This is in favor
of a local structural effect of mutation A9G on base-pair
12-23. Furthermore, intensity of cleavages is affected at a
distance from the mutation as well in the acceptor stem, the
T-domain, and the anticodon arm as within the D-domain.
The four tRNAs investigated sort into two sets based
on their nuclease susceptibilities, wild-type and variant
mt-tRNAAspG9/G12-C23 on one hand, and mutant mt-
tRNAAspG9/A12-U23 and variant mt-tRNAAspG9/U12-A23
on the other. The first tRNAs (Fig. 3A,C) show strong
V1-cuts within the acceptor stem (residue 68), anticodon
arm (residues 28, 29, and 30), and residue 25 (next to con-
nector 2), as well as weak V1-cuts within the T-loop
(residue 56). The second tRNAs (Fig. 3B,D) exhibit the
opposite strength in cleavage patterns, namely, weak
V1-cuts within the acceptor stem (residue 68), anticodon
arm (residues 28, 29, and 30), and residue 25 and a strong
V1-cut within the T-loop (residue 56). The opposite ribo-
nuclease V1 reactivity within the two sets is emphasized
on 3D folds (Fig. 3E,F) and suggests differential overall
flexibilities. Perturbations within the 9/12-23 interaction
influence stacking interactions downstream of the anti-
codon arm, upstream of base pair 12-23, and within the
FIGURE 1. Tertiary interaction network in canonical tRNAs. (A)
Secondary cloverleaf structure. (B) Tertiary ‘‘L-shaped’’ structure.
Structural domains are indicated, and the tertiary interaction network
is emphasized by dotted lines and boldface characters (for review, see
Giege´ et al. 1993; Dirheimer et al. 1995). Nucleotide positions
involved in the nine tertiary interactions are either strictly conserved,
semiconserved (Y for pyrimidine, R for purine), or not conserved
(black dots). Other strictly conserved or semiconserved nucleotides
are indicated by gray letters. Numbering is according to Juehling et al.
(2009). Residues 8, 9, and 26 form connectors between domains.
Residue 9 forms a triple by interaction with residue 23 of base-pair
12-23.
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T-loop and acceptor stem. In conclusion, 1) pathology-
related mutation A9G in connector 1 influences the overall
plasticity of the tRNA without breakdown of the secondary
or tertiary structure, but with subtle local and long-range
effects, and 2) effects of mutation A9G can be compensated
by a double transition at base-pair 12-23 in the D-stem.
Ricochet impact on functional properties
Aminoacylation properties (kcat and KM parameters) of the
four transcripts were determined by aspartylation assays in
the presence of human mt-AspRS (Table 1). As anticipated,
A9G mutation leads to a significant 27-fold loss of catalytic
efficiency (kcat/KM) with kcat value decreased 17-fold and
KM value increased 1.6-fold. Variant tRNA
AspG9/G12-C23
behaves similar to wild-type mt-tRNAAsp (with kcat and KM
values in the same range, i.e., KM of 1–2 mM and kcat of
1003 103 s-1). Variant tRNAAspG9/U12-A23 is a poor
substrate for mt-AspRS, with an estimated 470-fold loss in
aminoacylation efficiency. Interestingly, the kinetic prop-
erties for aspartylation overlap with the structural features,
with efficient aminoacylation of wild-type tRNAAsp and
FIGURE 2. Enzymatic structure probing of different human mt-
tRNAAsp transcripts. tRNAs were 59-labeled and treated with different
probes as indicated, cleavage products were separated on 12% poly-
acrylamide/8M urea gels, and tRNAs were revealed by autoradio-
graphy. Probing was conducted at 25°C using nuclease S1 and
ribonuclease V1. (C) Control; (L) alkaline ladder; (T1) denaturing
ribonuclease T1. Secondary structural domains are indicated. Nucleo-
tides that display different reactivities within the four transcripts are
highlighted by white (nuclease S1) and black (ribonuclease V1)
arrowheads. Bands corresponding to cleavages at residues 9, 12, and
23 are enclosed in rectangles.
FIGURE 3. Differential sensitivity of mt-tRNAAsp derivatives to en-
zymatic probes. (A–D) Cloverleaf structures. Mutated residues are
shown in boldface type for each variant. Only differential cleavages
between the four molecules are indicated. Black and white arrows
stand for cleavages by ribonuclease V1 and nuclease S1, respectively.
Large and small arrows correspond to strong and weak cleavages,
respectively. (E,F) L-shaped folds. Mt-tRNAAsp transcripts fall into
two structural sets according to their reactivity to ribonuclease V1. (E)
tRNAs active in aminoacylation and with unchanged reactivity to
enzymatic probes as compared with wild type. (F) tRNAs with altered
structures and impaired aminoacylation properties in comparison
with wild-type tRNA. The differential reactivities toward ribonuclease
V1 between the two sets are highlighted. Residue 9 and base-pair 12-
23 are boxed and indicated in boldface type. Other predicted tertiary
interactions in the core of the 3D structure are indicated by dotted
gray lines. Numbering is according to Pu¨tz et al. (2007).
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variant tRNAAspG9/G12-C23 but not mutant tRNAAspG9/
A12-U23 and variant tRNAAspG9/U12-A23. Conserved KM
values are consistent with retention of a global 3D structure
for all these molecules and their ability to be recognized by
mt-AspRS. Differences between kcat values reflect an effect
of the mutation on catalysis. This is linked to changes in the
overall plasticity of the molecules (as a long-range conse-
quence of the perturbation within the core of the tRNA
rather than to perturbed binding [Giege´ 2008]).
Residues 9-12-23 are partners in a tertiary interaction
in mammalian mt-tRNAs
The present data show that introduction of mutation A9G
into tRNAAsp leads to both structural perturbation and de-
crease in aminoacylation efficiency. It is possible to recover
both structure and function with a second site mutation in
the D-stem by replacing base-pair A12-U23 by G12-C23.
This reveals a link between the three nucleotides (Fig.
4A,C). This link is however broken within pathology-
related mutant and within variant G9/U12-A23 for which
no compensatory effects where found (Fig. 4B,D). In clas-
sical tRNAs, nucleotide 9 interacts with nucleotide 23
through their Hoogsteen faces (i.e., N7-face of purines,
C6-face of pyrimidines) (Kim et al. 1974; Westhof et al.
1985). A trans-Hoogsteen interaction is possible between
A9 and A23, as well as between G9 and C23, but not
between G9 and U23 (Leontis et al. 2002).
Analysis of the 136 available mammalian mt-tRNAAsp
sequences within the ‘‘Mamit-tRNA’’ database (Pu¨tz et al.
2007) allows a deeper insight into the conservation of resi-
dues 9, 12, and 23. Nucleotide 9 is strictly conserved
(100%) as an A residue. The combination of nucleotides
A9/A12-U23 (as in wild-type human mt-tRNAAsp) is pres-
ent in 97.8% of sequences, while in the 2.2% of remaining
cases, the combination A9/U12-A23 is found. Further com-
pilation of residues 9, 12, and 23 in the other tRNA families
within the database (except tRNASer(AGY) and tRNASer(UCN),
both having important deviating secondary structure fea-
tures) (Watanabe et al. 1994; Hayashi et al. 1997) reveals
that 12 tRNA families share local sequence features with
mt-tRNAAsp. All possess A9 and either A12-U23 or U12-
A23 (results not shown). Interestingly, three families [Ile,
Tyr, Leu(UUR)] possess a strongly conserved G residue at
position 9 and either A12-U23 or U12-A23 pairs, the
combinations present in the pathology-related tRNAAsp
mutant and in the noncompensating variant studied herein.
The natural existence of associations of nucleotides at posi-
tions 9, 12, and 23, experimentally found to be nonoptimal
in the frame of tRNAAsp, supports the importance of the
structural neighborhood of this triple. As seen in Figure 1B,
residues 9/12-23 are stacked in the middle of the core
domain in classical tRNAs. The existence of these neighbor-
ing tertiary interactions in mammalian mt-tRNAs needs to
be investigated in a systematic manner.
Altered tRNA flexibility as the primary molecular
effect of myopathy-related mutation A7526G
in human mt-tRNAAsp
The present data on aminoacylation and global structure
of the wild-type and mutant human mt-tRNAAsp reveal a
primary mechanism of impact of the pathology-related
mutation A7526G in vitro. The mutation alters the tRNA
structural plasticity, which in turn hampers aminoacyla-
tion. Several cases have been reported in which structural
impairments subsequently interfere with steps of the tRNA
life-cycle (for review, see Florentz et al. 2003; Wittenhagen
and Kelley 2003; Levinger et al. 2004). For example,







(103 s1 mM1) Loss
Wt mt-tRNAAspA9/A12-U23 2.35 6 0.10 121 6 0.44 51.63 1
Mutant mt-tRNAAspG9/A12-U23 3.83 6 2.24 7 6 2.09 1.88 27
Variant mt-tRNAAspG9/G12-C23 1.48 6 0.73 94 6 13.85 63.78 0.8
Variant mt-tRNAAspG9/U12-A23 NM NM 0.11 469
Loss values correspond to losses of catalytic efficiency relative to the wild-type human mt-tRNAAsp. For variant mt-tRNAAspG9/U12-A23, the
kcat/KM ratio was directly determined according to Schulman and Pelka (1988); NM, nonmeasurable.
FIGURE 4. Tolerated nucleotide combinations for positions 9-12-23
in human mt-tRNAAsp variants. The subdomain shown includes
connectors 1 and 2 and the D-stem. (A) Wild-type sequence. (B)
Pathology-related mutant A9G. (C) Sequence of variant G9/G12-C23
with a double transition in the D-stem. (D) Sequence of variant G9/
U12-A23 with a double transversion in the D-stem.
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mutation A4317G (A58G) in tRNAIle leads to an alternative
T-stem structure and structural fragility of the tRNA in-
compatible with aminoacylation (Kelley et al. 2001). Muta-
tion A3243G (A14G) in tRNALeu(UUR) leads to a two- to 10-
fold loss in aminoacylation efficiency and either to homo-
dimerization of the tRNA (Wittenhagen and Kelley 2002)
or to a rearrangement within the D-stem and loop (Sohm
et al. 2003). Mutation T3271C (T40C) in tRNALeu(UUR)
destabilizes the anticodon domain, which interferes with
binding of LeuRS (Wittenhagen et al. 2003). Pathological
mutations C5877T (C15A) and T5874C (A22G) in human
mt-tRNATyr trigger a structural destabilization in the D-loop
that propagates toward the anticodon arm and leads to a
loss of aminoacylation efficiency of 40- and 600-fold, respec-
tively (Bonnefond et al. 2008). Mutation A10044G (A59G)
induces a weaker interaction between the D- and the T-loops,
which perturbs interaction of mt-tRNAGly with the CCA
adding enzyme (Tomari et al. 2003).
The possibility that the structural perturbation intro-
duced by mutation A7526G (A9G) in tRNAAsp has func-
tional consequences outside the frame of aminoacylation
remains to be tested. Pathology-related mutation could, for
example, interfere with the local and/or global modification
pattern of the affected tRNA, which in turn could affect its
functional properties. Such situations were described for
mutations A3243G (A14G) in the D-loop of tRNALeu(UUR)
and A8344G (A55G) in the T-loop of tRNALys, which affect
the modification pattern in the D-domain (Helm et al.
1999a) and dominantly in the anticodon loops (Yasukawa
et al. 2001; Kirino et al. 2004). This hinders codon reading
and inhibits translation. Alteration of the post-transcrip-
tional modification patterns can also lead to accelerated
degradation of tRNAs (Kadaba et al. 2004). Pathology-
related mutation A7526G in mt-tRNAAsp affects a position
often methylated in mt-tRNAs (Juehling et al. 2009). In
human mt-tRNALys, m1A9 is a key modification for
optimal folding into a functional structure. This modifica-
tion hinders base-pairing of residue 9 with nucleotide 64
in the T-stem and shifts the dynamic equilibrium of a pre-
tRNA toward the functional structure (Helm et al. 1998,
1999b; Voigts-Hoffmann et al. 2007; Kobitski et al. 2008).
Methylation of residue 9 at atomic position 1 (a Watson–
Crick position) in mt-tRNAAsp would not interfere with
formation of the triple interaction (with residue 23 via a
Hoogsteen interaction) and might not be hindered by the
pathology-related mutation A9G. Indeed, the recent char-
acterization of the human mt-RNaseP revealed its associ-
ation with a G9 methyl-transferase activity, which might act
conjointly to 59-processing of the pre-tRNA (Holzmann
et al. 2008).
Outlook
More and more examples of human mt-tRNA mutations
with primary effects on tRNA structure are being reported,
including mutation A7526G (A9G) in mt-tRNAAsp, which
has further consequences for aminoacylation properties.
Dissecting the molecular incidence of the pathology-related
mutation in turn sheds light on structural features, that is,
the existence of a triple interaction involving residues 9, 12,
and 23 in human and mammalian mt-tRNAAsp. Fine-tuned
structural knowledge on ‘‘bizarre’’ mt-tRNAs remains of
fundamental necessity to allow understanding the precise
molecular mechanisms of many pathology-related mt-tRNA
mutations and to distinguish them from polymorphisms.
Exploration of the molecular impact of pathology-related
mutations will further help to decipher structural properties
of mt-tRNAs, and vice versa, structural knowledge on mt-
tRNAs will further help to unravel the impact of mutations.
MATERIALS AND METHODS
Human mitochondrial tRNA transcripts
and aspartyl-tRNA synthetase
Human mt-tRNAAsp has been cloned previously (Bonnefond et al.
2005). Derivative plasmids expressing mutant mt-tRNAAspG9/
A12-U23 and variants mt-tRNAAspG9/G12-C23 and mt-tRNAAspG9/
U12-A23 were obtained with the QuikChange Site-Directed
Mutagenesis Kit (Stratagene). In vitro transcriptions were per-
formed as described (Bonnefond et al. 2005). Human mt-AspRS
was previously cloned into pQE70 vector that introduces a (His)6-tag
to the C-term of the expressed protein. Overproduction and
purification steps were conducted as described (Bonnefond et al.
2005).
Aminoacylation assays
Assays were performed as described (Bonnefond et al. 2005) in 50
mM HEPES-KOH (pH 7.5), 25 mM KCl, 12 mM MgCl2, 2.5 mM
ATP, 0.2 mg/mL BSA, 1 mM spermine, 32 mM [3H]-aspartic acid
(208 Gbq/mmol), transcript, and enzyme. Transcripts were
renaturated by heating at 60°C for 60 sec in H2O and slow
cooling to room temperature before aminoacylation performed at
25°C. Kinetic parameters kcat and KM were derived from Line-
weaver-Burk plots obtained under adequate ranges of tRNA (100
nM to 4 mM) and mt-AspRS (12 nM to 500 nM). For mt-
tRNAAspG9/U12-A23 variant, direct determination of the ratio
kcat/KM was established as described in Schulman and Pelka
(1988). Experimental errors in kcat and KM varied at most by
20%. Numerical values are averages of at least four independent
experiments.
Structural mapping
Enzymatic probes specific for single-stranded (nuclease S1) and
double-stranded or highly structured domains (RNase V1) were
used. Labeling of transcript 59-end and subsequent purification of
tRNA molecules from polyacrylamide gels were carried out as
described earlier (Helm et al. 1998). Before probing, transcripts
were denaturated by heating at 60°C in H2O and slowly cooled
down to room temperature. Enzymatic digestions were performed
as described (Helm et al. 1998). Briefly, transcripts were incubated
in 50 mM HEPES-KOH (pH 7.5), 10 mM MgCl2, and 25 mM KCl
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for 5 min at 25°C. For digestion with S1 nuclease, 1 mM ZnCl2
was added. Reaction mixtures (10 mL) contained 30,000 Cerenkov
cpm of transcript supplemented with 2 mg of unlabeled Escher-
ichia coli total tRNA and either 12.8 U of nuclease S1 or 3.6 3
102 U of RNase V1. Cleavage reactions were performed during
5 min at 25°C and were stopped by adding one volume of 0.6 M
Na-acetate (pH 5.0), 3 mM EDTA, and 0.1 mg/mL E. coli total
tRNA followed by ethanol precipitation. Alkaline ladders were
performed by incubation of labeled transcripts (30,000 Cerenkov
cpm) and 2 mg of total tRNA from E. coli in 50 mM NaHCO3 (pH
9.0), at 80°C for 8 min. Guanine ladders were obtained by
incubation in 10 mM NaH2[C3H5O(COO)3] at pH 4.5, 3.2 M
urea, 0.4 mM EDTA for 4 min at 60°C followed by addition of 2 U
of T1 and a second incubation at 60°C for 4 min. Products of the
probing reactions were analyzed on 12% polyacrylamide/8M urea
denaturing gels. Controls without probes but supplemented with
ZnCl2 were run in parallel.
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